Please login to the form below

Not currently logged in
Email:
Password:

BMS drugs may alleviate hepatitis C without interferon

Combination daclatasvir and asunaprevir could offer "watershed moment" in treatment of the virus

Bristol-Myers Squibb (BMS) has published trial data which suggest that combination therapy with its hepatitis C drugs daclatasvir and asunaprevir has the potential to cure patients who have previously failed interferon-based therapy.

The phase II study, published in the New England Journal of Medicine (January 19), showed that the two directly-acting antiviral compounds achieved a sustained virologic response over 12 weeks of treatment.

If further results shows that these responses can be sustained for 48 weeks, then the regimen will be deemed curative.

Daclatasvir is the first NS5A replication complex inhibitor to be investigated in clinical trials and is currently in phase III development, said BMS, while asunaprevir is an NS3 protease inhibitor in phase II.

Combined use of directly-acting antivirals could provide patients with an all-oral alternative to the current standard of injectable therapy with interferon alpha, say the researchers.

Meanwhile, the study also showed that quadruple therapy with the two BMS compounds, pegylated interferon alpha and ribavirin achieved a sustained virologic response at week 12.

"Even with the recent approval of two protease inhibitors, treatment of hepatitis C patients who have not responded to PEG-interferon alfa and ribavirin has limited success," said the lead investigator in the trial, Anna Lok of the University of Michigan Medical School in Ann Arbor.

"Because of this high unmet medical need, there is a necessity for new combination regimens that can increase response rates in null responders," she added.

Currently, combination therapy with pegylated interferon alpha and ribavirin achieves sustained responses in just 50 to 80 per cent of patients - depending on the hepatitis C virus strain.

However, the availability of oral protease inhibitors - namely Vertex' Incivek (telaprevir) and Merck & Co's Victrelis (boceprevir) - has pushed response rates up.

In an editorial accompanying the NEJM study, Dr Raymond Chung, director of hepatology at Massachusetts General Hospital in Boston, described the findings as a "watershed moment" in treatment for chronic hepatitis C.

"We are on the threshold of a treatment revolution," he said.

20th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics